TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06309160

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COMPASS Across Settings (CAST)
Description: CAST will begin with an initial joint session with the student, caregiver, special education teacher, and pre-employment transition specialist that allows for discussion on the student's postsecondary goals, preferences, frustrations, challenges, and strengths related to social skills, adaptive/self-management, communication, problem behaviors, learning skills, and sensory sensitivities and preferences. This discussion will pinpoint critical social, communication, and work behavior/learning goals related to postsecondary goals and inform the intervention plans that are generated for each goal. Following this initial consultation, there will be four additional 1-hour sessions that incorporate evidence-based coaching, provided by the investigators, including performance feedback monitoring and instructional support. Each session is standardized and allows for assessment of student progress and intervention modification/self-reflection on the implementation of the intervention plans.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COMPASS Across Settings (CAST)
Description: CAST will begin with an initial joint session with the student, caregiver, special education teacher, and pre-employment transition specialist that allows for discussion on the student's postsecondary goals, preferences, frustrations, challenges, and strengths related to social skills, adaptive/self-management, communication, problem behaviors, learning skills, and sensory sensitivities and preferences. This discussion will pinpoint critical social, communication, and work behavior/learning goals related to postsecondary goals and inform the intervention plans that are generated for each goal. Following this initial consultation, there will be four additional 1-hour sessions that incorporate evidence-based coaching, provided by the investigators, including performance feedback monitoring and instructional support. Each session is standardized and allows for assessment of student progress and intervention modification/self-reflection on the implementation of the intervention plans.
Study: NCT06130514

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound-guided stellate ganglion block with 1% mepivacaine 5 mL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: Fluoroscopic-guided thoracic sympathetic ganglion block with 1% mepivacaine 3 mL
Study: NCT05063292

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Patients in Group II will receive active prewarming with an air forced blanket (full body blanket) 30 minutes prior to the operation
Description: Core temperature and 4-points skin temperatures measurements will be recorded all over the operation. Patients will be delivered 2 Litre/minute oxygen with a nasal cannula.Iv hydration will be continued by room temperatured balanced electrolyte solution with an infusion rate of 2mL/kg/hr. Spinal anesthesia will be applied at the level of L3-L4 by a 25 Gauge Quincke needle with a dose of 12.5-15 mg hyperbaric bupivacaine in the sitting position.
Study: NCT05879822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB099280
Description: Administered as specified in the treatment arm description
Study: NCT05340439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA 100 UNT [Xeomin]
Description: In cycle 1, a total body dose of 16U/kg (maximum 400U) of IncobotulinumtoxinA will be injected into the spastic muscles of the affected limbs.~In cycle 2, a total body dose of 19U/kg (maximum 475U) of IncobotulinumtoxinA will be injected. If a dose of 19U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 1 (16U/Kg; maximum 400U) may be administered in the cycle 2.~In cycle 3, a total body dose of 22U/kg (maximum 550U) of IncobotulinumtoxinA will be injected. If a dose of 22U/kg is not justified (i.e., for clinical or safety reasons) but BoNT-A treatment is still needed (according to the clinical condition of patients) the same dose injected in cycle 2 (19U/Kg; maximum 600U) may be administered in the cycle 3 (if the patient has been treated with 16U/kg in cycle 2, a dose of 19U/kg may be injected in cycle 3).
Study: NCT06047678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness
Description: A randomized single-blind controlled trial tested the hypothesis that different variants of resistance training (antagonistic lower and upper body training, agonistic lower and upper body training, and aerobic training) have different effects on blood pressure (systolic and diastolic), aortic pulse wave velocity (PWVao), and augmentation index (Aix) values and compared subjects with normotension and hypertension during and after exercise session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness
Description: A randomized single-blind controlled trial tested the hypothesis that different variants of resistance training (antagonistic lower and upper body training, agonistic lower and upper body training, and aerobic training) have different effects on blood pressure (systolic and diastolic), aortic pulse wave velocity (PWVao), and augmentation index (Aix) values and compared subjects with normotension and hypertension during and after exercise session.
Study: NCT06093672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: Oral.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxyurea
Description: Oral.
Study: NCT05430607

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Running therapy
Description: A 9-week running program.
Study: NCT04973423

Intervention type: RADIATION
Group type: OTHER
Intervention: MRI
Description: 2 additional MRI will be done for the CALM + MRI group
Study: NCT06530940

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Schirmer Test
Description: For each group, we will perform:~* SF measurement~* Buccal Schirmer test (BST) .

Intervention type: DIAGNOSTIC_TEST
Intervention: Buccal Schirmer Test
Description: For each group, we will perform:~* SF measurement~* Buccal Schirmer test (BST) .
Study: NCT06499038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Hip Arthroplasty
Description: Surgery for total hip replacement

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Hip Arthroplasty
Description: Surgery for total hip replacement
Study: NCT05931172

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual tasking
Description: Dual-task training is an emerging task-specific intervention that aims to improve reactive balance control after destabilizing perturbations in a safe and controlled environment. Dual tasking is given by therapist in unexpected directions to challenge patients reactive balance. In this study dual tasking will be given manually and on hurdles.~Daily 45 mins of exercise sessions of dual-task training like walking with talking , walking with a filled cup of water, walking with looking on clock performed for total eight weeks and 5 days a week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF(proprioceptive neuromuscular facilitation exercises)
Description: PNF involves both stretching and contracting (activation) of the muscle group being targeted in order to achieve maximum static flexibility, along with its D1\&D2 flexion/extension patterns to improve dynamic flexibility and thus improving balance and coordination.~total 8 weeks session will be given to patients. 45 mins session/each day for 5 days a week.
Study: NCT04950348

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Personalized TKA prosthesis
Description: TKA prosthesis that is designed and manufactured according to the patient's knee joint anatomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Zimmer NexGen prostheses
Description: Commercial products used on a large scale
Study: NCT05813431

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FRENCH grid (classification for emergency nurses in French hospitals)
Description: Triage tool validated by the French Society of Emergency Medicine (SFMU) which is used to prioritize patients according to standardized criteria and to orient them within the emergency department.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FRENCH grid (classification for emergency nurses in French hospitals)
Description: Triage tool validated by the French Society of Emergency Medicine (SFMU) which is used to prioritize patients according to standardized criteria and to orient them within the emergency department.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FRENCH grid (classification for emergency nurses in French hospitals)
Description: Triage tool validated by the French Society of Emergency Medicine (SFMU) which is used to prioritize patients according to standardized criteria and to orient them within the emergency department.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QuickSOFA
Description: Rapid score that consists of an evaluation based on 3 clinical criteria (blood pressure, respiratory rate and consciousness) to quickly establish a severity score.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: QuickSOFA
Description: Rapid score that consists of an evaluation based on 3 clinical criteria (blood pressure, respiratory rate and consciousness) to quickly establish a severity score.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Capillary lactate assessment
Description: Collect a drop of blood from the fingertip (less than 1 ml)
Study: NCT06409338

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation (active）
Description: Transcutaneous auricular vagus nerve stimulation was conducted by transcutaneous electrical stimulation therapy instrument to the cymba conchae of left ear in the vicinity of the auricular branch vagus nerve. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous auricular vagus nerve stimulation (sham）
Description: In the sham stimulation group, the electrodes were fixed at the left earlobe with the same stimulus parameters. Stimulation parameters: frequency = 20 Hz; pulse width = 500 μs, twice a day, 30 minutes each time.
Study: NCT04946435

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Antibiotic Irrigation
Description: The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic Irrigation
Description: The first 30 patients will be assigned to the control group to collect data on common nasal packing colonization and appropriate antibiotic selection for the experimental group. The following 30 patients will be assigned to the experimental group. Immediately following surgery, the control group will receive nasal packing alone and the experimental group will receive nasal packing with antibiotic irrigation
Study: NCT06539156

Intervention type: OTHER
Intervention: DVT prophyllaxis
Description: VTE prophylaxis administration among patients based on the American College of Chest Physicians (ACCP) recommendations

Intervention type: OTHER
Intervention: DVT prophyllaxis
Description: VTE prophylaxis administration among patients based on the American College of Chest Physicians (ACCP) recommendations
Study: NCT06182124

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Pneumococcal Vaccine - Formulation 1
Description: Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2) and Phase 2(Stage 3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent Pneumococcal Vaccine - Formulation 2
Description: Multivalent pneumococcal conjugate vaccine. This is a possible candidate for continuation in Phase 2 (Stage 2) and Phase 2(Stage 3).

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 20-valent pneumococcal conjugate vaccine (20vPnC)
Description: 20-valent pneumococcal conjugate vaccine (20vPnC)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Licensed pneumococcal comparator vaccine
Description: A licensed pneumococcal comparator vaccine
Study: NCT06436833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2-Liter polyethylene glycol plus elobixibat
Description: Take Elobixibat 10 mg, one day before colonoscopy at 8 a.m. Take Polyethylene glycol 1 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 1 Liter, at day of colonoscopy at 5 a.m.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4-Liter polyethylene glycol
Description: Take Polyethylene glycol 2 Liter, one day before colonoscopy at 8 p.m. Take polyethylene glycol 2 Liter, at day of colonoscopy at 5 a.m.
Study: NCT05190991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RPH-104
Description: solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Study: NCT05103904

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Given PO
Study: NCT06489743

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6-minute walk test (6MWT)
Description: 6-minute walk test (6MWT) will be performed according to clinical standards

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 6-minute walk test (6MWT)
Description: 6-minute walk test (6MWT) will be performed according to clinical standards
Study: NCT05441696

Intervention type: DEVICE
Intervention: ezCVP measurement
Description: * Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~* Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~* Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan).

Intervention type: DEVICE
Intervention: ezCVP measurement
Description: * Measuring device: non-FDA-cleared patient monitor (740E, Zoe Medical, MA, US), which has software to measure ezCVP.~* Sensor: an FDA-cleared pulse oximeter sensor for adults (K012891: DS-100A, Nellcor, CA, US).~* Cuff: an FDA-cleared NIBP cuff for adults (K080342: YP-713T, YP-714T or TP-715T, Nihon Kohden Corporation, Tokyo, Japan).
Study: NCT05986175

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery Training
Description: The motor imagery training will be given with an audio recording containing 15 minutes of motor imagery training. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stabilization Exercises
Description: Jeffreys' Core (body) Stabilization Exercises will be implemented. The protocol consists of exercises that progress gradually from the first level to the third level. The first level consists of static contraction training on a stable surface; the second level is dynamic training on stable surfaces; and the third level is dynamic and resistant training on an unstable surface. Each session is scheduled to last 45 minutes, with 5 minutes of heating and 5 minutes of cooling exercises. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stabilization Exercises
Description: Jeffreys' Core (body) Stabilization Exercises will be implemented. The protocol consists of exercises that progress gradually from the first level to the third level. The first level consists of static contraction training on a stable surface; the second level is dynamic training on stable surfaces; and the third level is dynamic and resistant training on an unstable surface. Each session is scheduled to last 45 minutes, with 5 minutes of heating and 5 minutes of cooling exercises. The protocol will be administered by a physiotherapist 3 times a week for 8 weeks.
Study: NCT05355974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Description: Norepinephrine continuous infusion at 0.10 mcg/kg/min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringers, Intravenous
Description: 500mL infusion run at 999mL/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringers, Intravenous
Description: 500mL infusion run at 999mL/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: normal saline
Description: 500mL infusion run at 999mL/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 500mL infusion run at 999mL/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Plasma-lyte
Description: 500mL infusion run at 999mL/hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plasma-lyte
Description: 500mL infusion run at 999mL/hr
Study: NCT05959122

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC serum iron serum ferritin
Description: 1. Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~2. Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC serum iron serum ferritin
Description: 1. Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~2. Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin

Intervention type: DIAGNOSTIC_TEST
Intervention: CBC serum iron serum ferritin
Description: 1. Fully automated blood cell counter (sysmex-Xs 800i) and AU 480-Chemistry auto-analyzer (Beckman Coulter Diagnostics-USA) was used for measurement of hemoglobin and serum iron levels~2. Chemiluminescence assay using an Abbott i2000SR analyser was used to measured serum ferritin
Study: NCT04162431

Intervention type: DIAGNOSTIC_TEST
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy
Study: NCT04879901

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: surface EMG
Description: surface EMG estimation with Carrying backpacks forward or backward
Study: NCT05455099

Intervention type: RADIATION
Intervention: Carotid ultrasound examination 1
Description: Participants will be assigned to obese group (body mass index 24.0-27.9 kg/m²). Carotid pulse wave velocity of all participants were measured by ultrafast ultrasound imaging technology using SuperSonic Imagine's explorer ultrasound system.

Intervention type: RADIATION
Intervention: Carotid ultrasound examination 2
Description: Based on the inclusion criteria, 1200 overweight Han people（body mass index ≥28.0 kg/m²） and both sexes will be recruited in the analysis. The values of ultrafast pulse wave velocity will be obtained.
Study: NCT06150547

Intervention type: DIAGNOSTIC_TEST
Intervention: FDG Positron Emission Tomography
Description: Imaging using an FDG radioactive tracer to look at the head.

Intervention type: DIAGNOSTIC_TEST
Intervention: Chemical Exchange Saturation Transfer Magnetic Resonance Imaging
Description: A noninvasive diagnostic test for measuring biochemical changes in the brain, especially the presence of tumors.
Study: NCT04162431

Intervention type: DIAGNOSTIC_TEST
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy

Intervention type: DIAGNOSTIC_TEST
Intervention: spectroscopic measurement
Description: measurement of the tissue with spectroscopy
Study: NCT06272630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWJ1464
Description: DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of DWJ1464
Description: Placebo of DWJ1464, TID, Duration of administration: 8 weeks, Visit: every 4 week
Study: NCT05712902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunvozertinib
Description: Daily dose of Sunvozertinib
Study: NCT05003531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose 2
Description: Participants will receive placebo or dose 2 IBI112 SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose 4
Description: Participants will receive placebo or dose 4 IBI112 SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose 1
Description: Participants will receive placebo or dose 1 IBI112 SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI112 dose 3
Description: Participants will receive placebo or dose 3 IBI112 SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Participants will receive placebo SC
Study: NCT06062680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine Tablets
Description: Three Herombopag Olamine Tablets is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine Tablets
Description: Three Herombopag Olamine Tablets is administered to healthy subjects.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine Tablets
Description: Three Herombopag Olamine Tablets is administered to healthy subjects.
Study: NCT04850846

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin XR
Description: Orally by mouth

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Orally by mouth
Study: NCT05458960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social needs navigator program
Description: 4 months of assistance tailored to the needs of the participant

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care
Description: Referral to United Way 2-1-1